Ligand id: 8920

Name: ublituximab

Compound class Antibody
International Nonproprietary Names
INN number INN
9334 ublituximab
LFB-R603 | TG-1101 | TGTX-1101
Ublituximab is a novel third-generation anti-CD20 monoclonal antibody, CD20 being the B lymphocyte cell surface glycoprotein encoded by the MS4A1 gene. This chimeric antibody has been glycoengineered (namely, having a low fucose content in its Fc region) to optimise FcγRIIIA (CD16a) binding, to enhance antibody-dependent cell-mediated cytotoxicity [1-2]. It is being investigated for its immunomodulatory potential.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ublituximab shows similar specificity and a similar glycosylation pattern to the anti-CD20 mAb EMAB-6 [1].
Database Links
Specialist databases
IMGT/mAb-DB 372
Other databases
GtoPdb PubChem SID 310264701
Search PubMed clinical trials ublituximab
Search PubMed titles ublituximab
Search PubMed titles/abstracts ublituximab